VenoVision News
7 articles
growth-positive
MassChallenge Announces 2023 HealthTech Cohort - MassChallenge
MassChallenge announces 37 startups invited to participate in its 2023 HealthTech cohort. The program offers a founders-first curriculum, industry connections, and funding opportunities. MassChallenge partners with MITRE to provide a Medicare and Medicaid curriculum and mentorship to the startups. The selected startups will benefit from the support of impact-driven enterprise partners and have the opportunity to collaborate with healthcare leaders. MassChallenge is a global network for innovators that aims to disrupt the status quo and create sustainable change. Since its launch in 2009, MassChallenge has supported over 4,000 startups and awarded over $18M in equity-free cash and prizes.
Partners
growth-positive
VenoVision selected for the Health Wildcatters 2022 Program in Texas to improve patient monitoring
VenoVision, a start-up specializing in non-invasive hemodynamic remote patient monitoring, has been selected to participate in the Health Wildcatters 2022 Program. The company aims to improve therapeutic management and patient outcomes while reducing healthcare costs. VenoVisions technology allows for objective and continuous monitoring of heart failure and other hemodynamic complications. The company was conceptualized in The Hebrew Universitys BioDesign program and has completed a proof-of-concept clinical trial. With the support of Health Wildcatters, VenoVision will establish partnerships and work towards commercialization. The company is based in Dallas, Texas.
Partners
Growth-Positive
Canada-Israel Cardiovascular Innovation ForumA Recap
On May 15, 2022, the Canada-Israel Cardiovascular Innovation Forum (CICI) held its second annual event, featuring six top-rated innovation projects from Israel and Canada. The forum was established in 2021 to encourage early-stage cardiovascular innovations in medical devices and digital health in both countries. It aims to establish collaboration between Israel and Canada in developing and funding cardiovascular innovations through competitions, grow a network of interested investors, and provide a vehicle for joint funding of promising early-stage projects and companies.
Partners
growth-positive
Patent Granted - US11234643B2 - Jugular venous assessment
The article discusses a patent (US20180184977A1) related to jugular venous assessment, which involves a method and device for measuring jugular vein parameters. The patent was originally filed by Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. and later assigned to Venovision Inc. The technology aims to enhance diagnostic capabilities for conditions related to the jugular vein. The patent was granted on February 1, 2022, and the current assignee is Venovision Inc.
Acquisition
growth-positive
MassChallenge Israel Announces 2021 Accelerator Program Cohort
MassChallenge Israel announces the 42 startups selected for its 2021 cohort. The startups were chosen from nearly 400 candidates from Israel and around the world. The program aims to prepare the entrepreneurs and early-stage companies to advance their social impact missions through mentorship, education, and connections. The startups cover various industries, including general, healthcare and life sciences, high tech, social impact, and energy and clean tech. MassChallenge Israel will also run sector-specific initiatives with corporate partners. The program concludes with ten prize winners receiving a business trip to Boston and New York City. MassChallenge Israel has raised over $520 million to date and created 11,000 jobs globally.
PartnersInvestment
InnoVEX Online The Innovation Hub of Asia
growth-positive
VENOVISION SELECTED FOR THE INAUGURAL IP² LAUNCHPAD TAIWAN-ISRAEL PROGRAM
VenoVision, an Israeli start-up, has been selected to participate in the IP² Launchpad Taiwan-Israel Program. The company offers an Ethical Artificial Intelligence-powered patient monitoring device that can detect early abnormalities in cardiorenal and cardiopulmonary patients. The device provides real-time data and uses AI to uncover potentially lifesaving insights. By participating in the program, VenoVision aims to gain access to medical industry leaders in Taiwan for regulatory clinical trials, investment, manufacturing, and sales. The company was initially a student project at the Hebrew Universitys BioDesign program and has since conducted human trials sponsored by Terumo Corporation in Japan.
PartnersInvestment
